San Antonio, TX, November 4, 2013 - Soricimed Biopharma Inc., a private clinical stage company developing novel cancer therapeutics and diagnostics, and Intrinsik, a leading provider of toxicology and regulatory affairs consulting services, announced today that Geoff Goodfellow, PhD, DABT, ERT, Director of Toxicology at Intrinsik Health Sciences Inc., will be presenting a poster entitled Rodent Toxicology Studies for a Novel Anti-Cancer Agent, SOR-C13 at the annual meeting of the American College of Toxicology.
SOR-C13 is a targeted peptide derived from the venom of the northern short-tailed shrew. It works by inhibiting a non-voltage gated calcium channel found in epithelial cancers such as ovarian, breast, prostate and others. It is currently being studied within a multicenter, open-label Phase I trial taking place at cancer centers in both Canada and the United States.
The pre-clinical toxicology study being presented was mandated by regulatory authorities and dictated the starting dose of Soricimed’s anti-cancer agent that could be safely tolerated by humans.
“This pre-clinical study was critical,” stated Professor Jack Stewart, Chief Scientific Officer, Soricimed Biopharma. “It helped us to understand what the body does with our anti-cancer agent and what our anti-cancer agent does to the human body. It was a key first step in finalizing the protocol for human trial.”
Soricimed’s Phase I trial will run from now to mid 2014. Based on successful results, further clinical trials will follow. Soricimed is hopeful that SOR-C13 could get to market in the next three to five years.
Soricimed Biopharma Inc., a private Canadian clinical stage company developing novel cancer therapeutics and diagnostics, was created in 2005 by Professor Jack Stewart and Paul Gunn following the discovery and development of a proprietary peptide, soricidin. Soricidin derivatives are the basis for Soricimed Biopharma Inc.’s targeted cancer management program focused on cancer therapeutics and diagnostics. Using focused innovative strategies in collaboration with major world-class cancer research institutions, Soricimed’s drugs have demonstrated a capability to reduce cancer cell viability, induce apoptosis and to reduce human tumour volume while minimizing side-effects in various classic animal and in vitro tumour models. Privately held, Soricimed is funded through private investors and various programs from the Government of Canada. For more information please visit, www.soricimed.com.
Intrinsik is an employee-owned, 50-person consultancy whose focus is to address the toxicology and regulatory challenges associated with the development of new products. In the last seven years, the team has been responsible for successfully driving over 70 nonclinical development programs for new human therapeutics. In addition, the team has been responsible for the preparation of numerous INDs (senior staff have been actively involved in over 100 successful INDs) and contributed to more than 20 NDAs during their careers. www.intrinsik.com
Julie Fotheringham - Partner, Hageman Communications